Dafni U, Martín-Lluesma S, Balint K, et al. - This work is identified to be the first meta-analysis on therapeutic vaccines for breast cancer (BC)/ovarian cancer (OC). Searching the PubMed electronic database, from January 1, 2000 to February 4, 2020, researchers identified 315 articles initially, of which, 67 were identified as eligible for inclusion in this meta-analysis (BC: 46, 1,698 patients; OC: 32, 426 patients; both BC/OC in 11). Testing of many alternative approaches has been performed in heterogeneous cohorts. More studies reported on dendritic-cell and peptide vaccines, 6/10 BC and 10/13 OC studies, respectively. These studies mostly included patients who had advanced disease and were heavily pretreated. Despite only modest response results, there were long survival rates and low toxicity. Median PFS was 2.6 months and 13.0 months for BC and OC respectively, while corresponding median OS was 24.8 months and 39.0 months. They emphasize performing more studies to evaluate basic mechanisms and improve vaccines' efficacy.